```html

X‑linked Recessive Muscular Dystrophy (Duchenne) – A Patient‑Focused Guide

Overview

Duchenne muscular dystrophy (DMD) is the most common and severe form of X‑linked recessive muscular dystrophy. It is a genetic disorder caused by mutations in the DMD gene, which encodes the protein dystrophin—a critical component that stabilizes muscle cell membranes during contraction.

• Who it affects: Primarily boys, because they have only one X chromosome. Girls can be carriers and, in rare cases, may show mild symptoms.
• Prevalence: Approximately 1 in 3,500–5,000 male newborns worldwide are affected, making DMD the most frequent childhood muscular dystrophy (CDC, 2023).
• Typical age of onset: Early childhood, usually between ages 2–5, when motor milestones begin to falter.

Symptoms

Symptoms progress in a predictable pattern as muscle fibers are replaced by fatty and fibrous tissue. Below is a complete list with brief descriptions.

Early childhood (2‑5 years)

• Delayed motor milestones: Trouble walking, running, or climbing stairs.
• Gower’s sign: The child uses hands to “walk” up their thighs to stand from the floor.
• Frequent falls: Often due to weak calf muscles (pseudohypertrophy) that feel enlarged but are not strong.
• Difficulty rising from a supine position.

School‑age (5‑12 years)

• Progressive muscle weakness: Begins proximally (hip and shoulder girdles) and spreads distally.
• Contractures: Tightening of muscles and tendons, especially at elbows, knees, and ankles.
• Cardiomyopathy: Silent early; may present as fatigue or shortness of breath during activity.
• Respiratory muscle weakening: Reduced cough strength, leading to more respiratory infections.

Adolescence and early adulthood (12‑25 years)

• Loss of ambulation: Most patients become wheelchair‑bound by age 12‑14.
• Severe scoliosis: Curvature of the spine due to weak back muscles.
• Cardiac complications: Dilated cardiomyopathy, arrhythmias, heart failure.
• Respiratory failure: Need for nighttime non‑invasive ventilation (NIV) or assisted coughing.

Other possible features

• Learning difficulties or attention‑deficit disorder (affects ~30% of patients).
• Gastroesophageal reflux due to weakened diaphragm.
• Osteopenia/osteoporosis from reduced weight‑bearing activity.

Causes and Risk Factors

Genetic Basis

DMD results from mutations—most often deletions, duplications, or point mutations—in the DMD gene located at Xp21.2. The gene is one of the largest in the human genome (2.2 Mb), which makes it prone to errors during DNA replication.

Inheritance Pattern

• X‑linked recessive: A mother who carries one defective copy has a 50% chance of passing the mutation to each son (who will be affected) and a 50% chance of passing it to each daughter (who becomes a carrier).
• De‑novo mutations: About one‑third of cases arise spontaneously in families with no prior history.

Risk Factors

• Being male (only one X chromosome).
• Family history of DMD or other X‑linked muscular dystrophies.
• Maternal age: Advanced maternal age slightly increases the risk of de‑novo mutations.

Diagnosis

Early diagnosis is crucial for initiating therapy and family counseling.

Clinical Evaluation

• History of delayed milestones and Gower’s sign.
• Physical exam noting calf pseudohypertrophy, contractures, and muscle weakness.

Laboratory Tests

• Creatine kinase (CK) level: Often >10‑times normal in early disease.

Genetic Testing

• Multiplex ligation‑dependent probe amplification (MLPA): Detects common deletions/duplications.
• Next‑generation sequencing (NGS): Identifies point mutations and small indels.
• Genetic confirmation provides eligibility for mutation‑specific therapies (e.g., exon‑skipping).

Imaging & Functional Studies

• Muscle MRI: Shows patterns of fatty infiltration; useful for monitoring progression.
• Electromyography (EMG): Demonstrates myopathic changes.
• Cardiac evaluation: Baseline echocardiogram and ECG; repeat annually.
• Pulmonary function tests (PFTs): Forced vital capacity (FVC) tracking.

Treatment Options

While there is no cure, a multimodal approach can slow progression, improve quality of life, and extend life expectancy (average into the 30s–40s with modern care). Treatment is individualized and often coordinated by a neuromuscular clinic.

Pharmacologic Therapies

• Corticosteroids (prednisone, deflazacort): First‑line; delays loss of ambulation by 2‑3 years and improves pulmonary function. Typical dose: 0.75 mg/kg/day prednisone.
• Exon‑skipping agents:
  • Eteplirsen (exon 51 skip) – FDA‑approved for amenable mutations.
  • Golodirsen (exon 53), Viltolarsen (exon 53), Casimersen (exon 45).
• Nonsense‑mutation read‑through: Ataluren (for stop‑codon mutations).
• Cardiac medications: ACE inhibitors or ARBs (e.g., enalapril) when left ventricular dysfunction appears; beta‑blockers for arrhythmias.
• Bone health: Vitamin D and calcium supplementation; bisphosphonates for osteoporosis.

Non‑Pharmacologic Interventions

• Physical therapy: Stretching, low‑impact aerobic exercise, and strengthening of preserved muscles.
• Orthopedic surgery: Tendon releases, scoliosis correction, and foot orthoses to maintain alignment.
• Respiratory support:
  • Night‑time non‑invasive ventilation (BiPAP) once FVC < 50% predicted.
  • Mechanical cough assist devices.
• Assistive devices: Wheelchairs (power or manual), standing frames, and adaptive equipment for schooling/work.
• Nutrition: High‑protein, calorie‑dense diet; monitor for obesity which worsens respiratory burden.

Emerging & Investigational Therapies

• Gene replacement using micro‑dystrophin AAV vectors (clinical trials ongoing).
• CRISPR‑based genome editing (pre‑clinical).
• Stem‑cell transplantation and exon‑editing approaches.

Living with X‑linked Recessive Muscular Dystrophy (Duchenne)

Daily Management Tips

• Routine stretching: Perform gentle stretches for hips, knees, ankles, and shoulders at least twice daily to delay contractures.
• Energy conservation: Plan activities with rest breaks; use a power wheelchair early to preserve upper‑body strength.
• Respiratory hygiene: Use a handheld or mechanical cough assist after meals and before sleep.
• Cardiac monitoring: Keep appointments for echocardiograms every 6‑12 months; report palpitations or dizziness promptly.
• School & work accommodations: Request individualized education plans (IEPs) or workplace modifications (e.g., accessible desks, assistive tech).
• Psychosocial support: Connect with patient advocacy groups (e.g., Parent Project Muscular Dystrophy) for counseling and community resources.
• Family planning: Carrier testing and pre‑implantation genetic diagnosis (PGD) are available for families who wish to have children.

Nutrition & Bone Health

Maintain a balanced diet rich in calcium and vitamin D. Consider a dietitian’s guidance for calorie needs as mobility declines, and schedule bone‑density scans every 2‑3 years.

Vaccinations

Influenza and pneumococcal vaccines are strongly recommended to reduce respiratory infection risk.

Prevention

Because DMD is genetic, primary prevention is limited to informed reproductive choices.

• Carrier screening: Women with a family history should consider genetic testing before or during pregnancy.
• Prenatal diagnosis: Chorionic villus sampling or amniocentesis can detect DMD mutations.
• Pre‑implantation genetic diagnosis (PGD): Allows selection of embryos without the pathogenic DMD mutation during IVF.
• Genetic counseling: Essential for carriers and families to understand recurrence risks.

Complications

If left untreated or inadequately managed, DMD can lead to serious, life‑threatening problems.

• Cardiomyopathy: Dilated left‑ventricular dysfunction and arrhythmias; leading cause of mortality.
• Respiratory failure: Progressive hypoventilation, nocturnal apnea, and susceptibility to pneumonia.
• Severe scoliosis: Can impair lung capacity and cause chronic pain.
• Contractures & joint deformities: Limit care access and increase risk of pressure sores.
• Psychiatric issues: Depression, anxiety, and social isolation are common.
• Bone fractures: Due to low bone mineral density and falls.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, Peer‑reviewed articles from Neurology and Muscle & Nerve (2022‑2024).

```